tiprankstipranks

James Breitmeyer Insider Profile

4 Followers
James Breitmeyer, Director at Zogenix, holds 1.25K shares in Zogenix (Ticker: ZGNX), holds ― shares in Otonomy (Ticker: OTIC), holds 655.74K shares in Oncternal Therapeutics (Ticker: ONCT).
tipranks
James Breitmeyer

James Breitmeyer
Zogenix (ZGNX)
Director

Ranked #55,906 out of 99,335 Corporate Insiders

Profitable Transactions

50%
1 out of 2 Profitable Transactions

Average Return

-7.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$748K
100.00%
A breakdown of James Breitmeyer's holdings

Insider Roles

Oncternal Therapeutics
(ONCT)
CEO, Director
Roles that James Breitmeyer holds in companies

Most Profitable Insider Trade

Stock:
Oncternal Therapeutics
(ONCT)
Rating:Informative Buy
Date:Apr 17, 2023 - Apr 17, 2024
Return:+25.00%
The most profitable trade made by James Breitmeyer

James Breitmeyer's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ZGNX
Zogenix
Mar 26, 2014
Uninformative Buy
$33.35K
OTIC
Otonomy
Oncternal Therapeutics
Jan 05, 2024
CEO, Director
Uninformative Sell
27.17K
$747.54K
CADX
Cadence Pharma
List of latest transactions for each holding click on a transaction to see James Breitmeyer's performance on stock

James Breitmeyer insider profile FAQ

What is the percentage of profitable transactions made by James Breitmeyer?
The percentage of profitable transactions made by James Breitmeyer is 50%.
    What is the average return per transaction made by James Breitmeyer?
    The average return per transaction made by James Breitmeyer is -7.50%.
      What stocks does James Breitmeyer hold?
      James Breitmeyer holds: ZGNX, OTIC, ONCT, CADX stocks.
        What was James Breitmeyer’s latest transaction?
        James Breitmeyer latest transaction was an Uninformative Buy of ―.
          What was James Breitmeyer's most profitable transaction?
          James Breitmeyer’s most profitable transaction was an Informative Buy of ONCT stock on April 17, 2023. The return on the trade was 25.00%.
            What is James Breitmeyer's role in Zogenix?
            James Breitmeyer's role in Zogenix is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.